首页> 外文期刊>Drug Design, Development and Therapy >Design and in vitro/in vivo evaluation of sustained-release floating tablets of itopride hydrochloride
【24h】

Design and in vitro/in vivo evaluation of sustained-release floating tablets of itopride hydrochloride

机译:盐酸伊托必利缓释片的设计及体内外评价

获取原文
           

摘要

Purpose: The aim of the present study was to improve the bioavailability of itopride (ITO) and sustain its action by formulating as a floating dosage form. Materials and methods: Sustained-release floating tablets of ITO hydrochloride (HCl) were prepared by direct compression using different hydrocolloid polymers such as hydroxypropyl methylcellulose and ethylcellulose and/or methacrylic acid polymers Eudragit RSPM and Carbopol 934P. The floating property was achieved using an effervescent mixture of sodium bicarbonate and anhydrous citric acid (1:1?mol/mol). Hardness, friability, content uniformity, and dissolution rate of the prepared floating tablets were evaluated. The formulation F10 composed of 28.5% Eudragit RSPM, 3% NaHCO3, and 7% citric acid provided sustained drug release. Results: In vitro results showed sustained release of F10 where the drug release percentage was 96.51%±1.75% after 24?hours ( P =0.031).The pharmacokinetic results indicated that the area under the curve (AUC0–∞) of the prepared sustained-release floating tablets at infinity achieved 93.69?μg·h/mL compared to 49.89?μg·h/mL for the reference formulation (Ganaton?) and the relative bioavailability of the sustained-release formulation F10 increased to 187.80% ( P =0.022). Conclusion: The prepared floating tablets of ITO HCl (F10) could be a promising drug delivery system with sustained-release action and enhanced drug bioavailability.
机译:目的:本研究的目的是通过配制为浮动剂型来改善伊托必利(ITO)的生物利用度并维持其作用。材料和方法:使用不同的水解胶体聚合物(例如羟丙基甲基纤维素和乙基纤维素和/或甲基丙烯酸聚合物Eudragit RSPM和Carbopol 934P)直接压片,制备ITO盐酸盐(HCl)的缓释漂浮片。使用碳酸氢钠和无水柠檬酸(1:1?mol / mol)的泡腾混合物来实现漂浮性。评价了所制备的漂浮片剂的硬度,脆性,含量均匀性和溶解速率。由28.5%的Eudragit RSPM,3%的NaHCO 3 和7%的柠檬酸组成的制剂F 10 提供了持续的药物释放。结果:体外实验结果显示F 10 持续释放,24小时后药物释放率为96.51%±1.75%(P = 0.031),药代动力学结果表明曲线下面积(所制备的无限量缓释浮片的AUC 0–∞ )达到93.69?μg·h / mL,而参考制剂为49.89?μg·h / mL(Ganaton ?< / sup>),缓释制剂F 10 的相对生物利用度增加到187.80%(P = 0.022)。结论:制备的ITO HCl(F 10 )漂浮片具有持续释放作用和增强的药物生物利用度,有望成为一种有前景的药物传递系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号